The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 103 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Antineoplastic Combined Chemotherapy Protocols  [Clear All Filters]
Journal Article
Wu, S-C., Li L. S., Kopp N., Montero J., Chapuy B., Yoda A., et al. (2015).  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.. Cancer Cell. 28(1), 29-41.
Pentheroudakis, G., Kotoula V., Koliou G-A., Karavasilis V., Samantas E., Aravantinos G., et al. (2018).  AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.. Clin Colorectal Cancer. 17(4), e631-e637.
Pectasides, D., Papaxoinis G., Nikolaou M., Valavanis C., Aravantinos G., Fountzilas G., et al. (2009).  Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.. Anticancer Res. 29(2), 737-44.
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Pentheroudakis, G., Mavroeidis L., Papadopoulou K., Koliou G-A., Bamia C., Chatzopoulos K., et al. (2019).  Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.. Clin Colorectal Cancer. 18(4), e370-e384.
Apalla, Z., Lallas A., Tzellos T., Sidiropoulos T., Lefaki I., Trakatelli M., et al. (2014).  Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.. Br J Dermatol. 170(4), 809-15.
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.. Eur J Haematol. 98(6), 563-568.
Dimopoulos, M. A., Roussou M., Gavriatopoulou M., Psimenou E., Eleutherakis-Papaiakovou E., Migkou M., et al. (2016).  Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.. Am J Hematol. 91(5), 499-502.
Pectasides, D., Fountzilas G., Papaxoinis G., Pectasides E., Xiros N., Sykiotis C., et al. (2009).  Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.. Int J Gynecol Cancer. 19(4), 777-81.
Katirtzoglou, N., Gkiozos I., Makrilia N., Tsaroucha E., Rapti A., Stratakos G., et al. (2010).  Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.. Clin Lung Cancer. 11(1), 30-5.
Vamvakas, L., Athanasiadis A., Karampeazis A., Kakolyris S., Polyzos A., Kouroussis C., et al. (2010).  Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).. Crit Rev Oncol Hematol. 76(1), 61-70.
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Tsalis, K., Vasiliadis K., Christoforidis E., Vergos O., Angelopoulos S., Botsios D., et al. (2004).  Current treatment of colorectal liver metastases.. Tech Coloproctol. 8 Suppl 1, s174-6.
Manola, K. N., Panitsas F., Polychronopoulou S., Daraki A., Karakosta M., Stavropoulou C., et al. (2013).  Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.. Cancer Genet. 206(3), 63-72.
Kastritis, E., Gavriatopoulou M., Kyrtsonis M-C., Roussou M., Hadjiharissi E., Symeonidis A., et al. (2015).  Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.. Blood. 126(11), 1392-4.
Diamantidis, M. D., Papadopoulos A., Kaiafa G., Ntaios G., Karayannopoulou G., Kostopoulos I., et al. (2009).  Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task.. Int J Hematol. 90(2), 226-9.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Karavasilis, V., Kosmidis P., Syrigos K. N., Mavropoulou P., Dimopoulos M. A., Kotoula V., et al. (2014).  Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.. Anticancer Res. 34(10), 5649-55.
Xenidis, N., Chelis L., Amarantidis K., Chamalidou E., Dimopoulos P., Courcoutsakis N., et al. (2012).  Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.. Cancer Chemother Pharmacol. 69(2), 477-84.
Saloustros, E., Malamos N., Boukovinas I., Kakolyris S., Kouroussis C., Athanasiadis A., et al. (2014).  Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).. Breast Cancer Res Treat. 148(3), 591-7.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Han, L. Y., Karavasilis V., van Hagen T., Nicum S., Thomas K., Harrison M., et al. (2010).  Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.. Eur J Cancer. 46(8), 1359-64.
Maniadakis, N., Dafni U., Fragoulakis V., Grimani I., Galani E., Fragkoulidi A., et al. (2009).  Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.. Ann Oncol. 20(2), 278-85.
Christodoulou, C., Dafni U., Aravantinos G., Koutras A., Samantas E., Karina M., et al. (2009).  Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.. Anticancer Res. 29(2), 693-702.
De Roock, W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. (2010).  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.. Lancet Oncol. 11(8), 753-62.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.